Gus Johnson
Assistant Director
Get their honest, personalized take on your startup.
Sign in to pitch Gus →At a glance
- Full Name
- Gus Johnson
- Title
- Assistant Director (also described in aggregator listings as Portfolio Manager), UT Horizon Fund
- Firm
- UT Horizon Fund — The University of Texas System (Office of Talent & Innovation)
- Firm Type
- University-sponsored strategic venture fund (angel/co-investor)
- Investment Stage
- Formative/early stage (seed and early rounds)
- Check Size
- Not publicly disclosed; the fund invests from ~$50M in committed capital and participates as a co-investor rather than lead
- Target Company Profile
- Companies with a technology license agreement with — or equity ownership by — a UT System institution, with a full-time CEO, an implemented business strategy, and a reasonable expectation of raising additional investor capital in the round
- Sector Focus
- Life sciences / biopharma, medical devices, neurostimulation, healthcare IT, information technology, software, and communications technology (spun out of UT research)
- Geographic Focus
- Texas / UT System–affiliated companies
- Location
- Denver, CO (works with the Austin-based UT System fund)
Background
Gus Johnson is the Assistant Director of the UT Horizon Fund, the strategic venture capital fund of the University of Texas System, housed within the System's Office of Talent & Innovation. Created by the UT System Board of Regents in 2011, the fund carries a dual mandate — improving the commercialization of technologies developed at UT System institutions while generating positive financial returns — and Johnson helps manage its portfolio and sourcing of new investments from UT-affiliated startups.
Johnson is a healthcare-finance executive who describes himself as having 15+ years of experience "driving growth and value creation." Before and alongside his fund role, he has held operating and finance positions tied to several UT Horizon portfolio companies, including Astrocyte Pharmaceuticals, MicroTransponder, MolecularMatch, and GenXComm (GXC) — companies spanning brain-injury therapeutics, neurostimulation, oncology genomics, and full-duplex wireless technology. That operator-plus-investor background is unusually well matched to the fund's science- and healthcare-heavy deal flow.
He earned an MBA in Finance from Emory University's Goizueta Business School. He is based in the Denver, Colorado metropolitan area while working with the UT System fund, which is administered from Austin, Texas.
Investment Thesis & Focus
- Invests only in companies with tangible ties to UT System institutions — those holding a technology license from a UT institution or in which a UT institution holds equity.
- Backs formative/early-stage ventures that already have a full-time CEO, a business strategy underway, and line of sight to additional capital in the current round.
- Acts explicitly as "a collaborative co-investor and a committed long-term partner" — the fund states it "does not price or lead a round," instead co-investing alongside professional venture and angel investors.
- Concentrates on deep-tech and health/life-sciences commercialization: biopharma, medical devices, neurostimulation, diagnostics/genomics, healthcare IT, and communications/IT software.
- Positioned as part of the broader Texas startup ecosystem, aiming to help "System-related companies create social and financial wealth."
Notable Investments
- Astrocyte Pharmaceuticals — therapeutics for brain injury via selective astrocyte activation (Johnson associated with the company).
- MicroTransponder — neurostimulation devices for neurological conditions (e.g., stroke rehabilitation); Johnson associated with the company.
- MolecularMatch — uses genetics to match cancer patients with clinical trials (Johnson associated with the company).
- GenXComm (GXC) — self-interference-cancellation / full-duplex wireless communications technology (Johnson associated with the company).
- Lung Therapeutics (Aileron/Lung) — clinical-stage biopharma for pulmonary indications.
- Emtora Biosciences — rapamycin-based cancer-prevention drug formulation.
- Alafair Biosciences — biomaterials/biomedical devices for internal wound healing.
- Cerebri AI — software analyzing and quantifying customer experience/journeys.
- Quantified Communications — SaaS communication analytics.
- EMIT Corporation — products to treat and prevent hypothermia.
- Decisio Health — clinical decision-support / risk-analysis software (cited among fund investments).
Unlock the full research
Get how to approach them, recent activity, sources, contact links — plus pitch their AI twin for a candid read on your raise.
One-time. Stays unlocked for you.